Loading…
Effective Screening and Testing for Tuberculosis Act
Legislative Progress
Introduced
December 11, 2023
Latest Action
December 15, 2023
Primary Sponsor
John R. MoolenaarRepublican(MI)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
62pct
4d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2024 · fourth_quarter · Health Issues
H.R.7188/S.3733 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)
Client expense: Not reported · Firm income: $50,000
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Issues related to Human Cellular Tissue Products (HCTP)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE